Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Oraxol in Cutaneous Angiosarcoma
2019-002085-13Phase 2Unknown
- Sponsor
- Athenex
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel + encequidar in cutaneous angiosarcoma and angiosarcoma, sponsored by Athenex. Primary endpoint: Response rate within 6 months (RR6 months). Status: unknown.
02
Drugs
paclitaxel + encequidar
03
Conditions
cutaneous angiosarcomaangiosarcoma
Beyond the preview
Go deeper on 2019-002085-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002085-13.